ReShape Lifesciences Inc

ReShape Lifesciences — EnteroMedics — Technical Presentation (November 2009)

7 slides from ReShape Lifesciences's technical presentation, Nov 12, 2009

  1. Slide 1: EMPOWER Study Summary of Ongoing Review

    EMPOWER Study Summary of Ongoing Review November 2009 Exhibit 99.3

  2. Slide 2: EWL from Initiation and from Implant

    EWL from Initiation (primary efficacy endpoint, MetLife) EWL from Implant (BMI) By <9 hours VBLOC Therapy VBLOC Therapy 12.1% 16.6% Control 12.0% 16.4% By >= 9 hours use/day (prescribed): 128 of 253 subjects (51%) Average hours of use: 10.9 hours/day VBLOC Therapy 18.3% 23.1% Control 17.8% 22.6% use

  3. Slide 3: Optimal Hours of Usage

    Optimal Hours of Usage Mean EWL from Implant (BMI Method) with Standard Error at 12 Months by Categories of Average Hours of Use per Day through 12 Months

  4. Slide 4: EWL Through Months

    EWL Through 12 Months Mean EWL from Implant (BMI Method) by Average Hours of Use per Day with Standard Error for 12 Month Completer Cohort -30 -25 -20 -15 -10 -5 Study Visit < 9 hours/day >= 9 hours/day N=125 N=128 p<0.0001 at 6 and 12 Months N=118 N=126 Average Use = 6.9 hrs/day Average Use = 10.9

  5. Slide 5: Safety Outcomes: Serious Adverse Events (SAEs)

    Clinical Events Committee- Adjudicated Relatedness of SAE (Event Origin) VBLOC Therapy N=192 Control N=102 Overall N=294 Safety Outcomes: Serious Adverse Events (SAEs) No deaths No Unanticipated Adverse Device Effects (UADEs) 30 SAEs (see table below) No therapy-related SAEs Device 3 (1.6%) 1 (1.0%)

  6. Slide 6: Safety Outcomes: Study Withdrawals

    Safety Outcomes: Study Withdrawals 8.5% of patients withdrew in the first 12 Months

  7. Slide 7: EMPOWER Study Summary of Ongoing Review

    EMPOWER Study Summary of Ongoing Review November 2009

EnteroMedics — Technical Presentation (November 2009) on 6ix